利伐沙班治疗静脉血栓最佳服用时间？

The best time to take for the treatment of venous thrombosis varies according to different drug specifications. For example, rivaroxaban 10 mg is best taken after meals or with food. Rivaroxaban 15 mg or 20 mg tablets are best taken with food, and you can choose to take it with meals.

Rivaroxaban

Rivaroxaban is administered orally, and the recommended dose is 10 mg of rivaroxaban, once daily. If a dose is missed during this period, rivaroxaban should be taken immediately and continued once daily the next day.

The recommended dose for initial treatment of acute DVT or PE is 15 mg twice daily for the first three weeks. After the initial treatment period, the recommended dose for subsequent treatment is 20 mg once daily, administered at approximately the same time each day.

The efficacy of rivaroxaban is not affected by dietary intake, so it can be taken before, during or after meals. This makes postoperative anticoagulation more convenient for patients and increases patients’ compliance with anticoagulation after discharge.

Rivaroxaban

As a new type of oral anticoagulant, rivaroxaban is currently a commonly used drug for the treatment of venous thrombosis. It is a factor

Rivaroxaban has the advantages of convenient administration, rapid onset of action, and few complications. At the same time, it has a good therapeutic effect on deep vein thrombosis caused by infusion catheters, has a low risk of bleeding and a very high catheter retention rate, and can also prevent subsequent venous thromboembolism events. It has been recommended abroad as the first choice anticoagulant for tumor patients.

Research by domestic scholars has shown that rivaroxaban is effective in treating cancer patients with PICC-related acute upper limb deep vein thrombosis. Moreover, the metabolites of rivaroxaban can be excreted in urine and feces and will not remain in the body, so it is safe.

Taking rivaroxaban

Rivaroxaban has definite efficacy and good patient compliance. During clinical use, special attention should be paid to bleeding-related adverse reactions. Rivaroxaban's incomplete absorption in the gastrointestinal tract and its effects on the mucosa may be one of the reasons why it easily leads to gastrointestinal bleeding. Therefore, gastrointestinal bleeding is a risk that requires close monitoring when using rivaroxaban clinically.

At the same time, the drug must be used with caution in certain special patient groups, such as children, patients with renal insufficiency, patients receiving additional antithrombotic therapy, patients with poor compliance, and patients with a high risk of gastrointestinal bleeding.

Due to a lack of safety and efficacy data, rivaroxaban is not recommended for use in adolescents or children under 18 years of age. During clinical application, attention should be paid to bleeding phenomena and changes in liver and kidney functions.

References

1. [1] Bo Zhengwen, Huang Jiang, An Shuai, Li Zheng, Feng Mingli, Cao Guanglei, Shen Huiliang. Clinical research progress on the use of anticoagulants to prevent deep vein thrombosis after total knee replacement [J]. Chinese Journal of Bone and Joint, 2018, 7(04): 292-296.

2. [1] Du Xiaoming, Zhu Meiting, Suga Lingyan. Investigation and analysis of clinical application of rivaroxaban [J]. Chinese Pharmaceutical Journal, 2019, 54(06): 494-500.

Recommended related articles: